ApoB、非HDL-C与LDL-C目标指导一级预防降脂治疗的成本效益
该经济评估用计算机模拟模型,基于2005-2016年NHANES中250 000名符合他汀条件且无ASCVD的美国成人,比较以LDL-C、非HDL-C或ApoB目标强化降脂治疗的成本效益。以ApoB目标相较非HDL-C目标可获1324 QALYs,增量成本效益比为每QALY 30 300美元。在每QALY 120 000美元支付意愿阈值下,ApoB目标在65%概率分析中为最优策略。
要点
- 以ApoB目标强化一级预防降脂治疗,增量成本效益比为每QALY 30 300美元。
- 在每QALY 120 000美元阈值下,ApoB目标在65%概率分析中为最优策略。
- ApoB检测成本影响有限,较高成本主要反映寿命延长与预防治疗时间延长。
核心结论
- 计算机模拟研究提示,ApoB可作为指导一级预防降脂治疗且具成本效益的标志物,并改善人群健康。
研究设计与样本
- 经济评估采用计算机模拟模型,评估以LDL-C、非HDL-C或ApoB目标强化降脂治疗的成本效益。
- 构建250 000名符合他汀条件且无ASCVD的美国成人队列,基于2005-2016年NHANES参与者(N=4149)。
- 个体在血脂筛查后开始模拟,并按2018年AHA/ACC指南接受他汀治疗。
- 模型输入来自全国调查数据、汇总纵向队列研究和已发表文献,并用传统与概率敏感性分析探索不确定性。
主要发现
- 在每QALY 120 000美元支付意愿阈值下,ApoB目标在65%概率分析中为最优,非HDL-C目标在25%中为最优。
- ApoB检测成本影响有限,较高成本反映寿命延长与预防治疗时间延长。
关键数值与推荐
- 当治疗后LDL-C未低于100 mg/dL、非HDL-C未低于118 mg/dL或ApoB未低于78.7 mg/dL时强化降脂治疗。
- 结局为终生质量调整生命年(QALYs)与成本(2025年美元),年贴现率3.0%。
- 主要结局为增量成本效益比;每QALY成本低于120 000美元视为具成本效益。
临床怎么用
- 一级预防降脂治疗可考虑以ApoB目标指导强化治疗,以提升成本效益。
- 在支付意愿阈值为每QALY 120 000美元时,ApoB目标在多数概率分析中为最优策略。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Apolipoprotein B (apoB) is a superior marker of residual atherosclerotic cardiovascular disease risk in patients treated with lipid-lowering therapy (LLT) compared with low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C). The cost-effectiveness of LDL-C, non-HDL-C, and apoB goals has not been established. OBJECTIVE: To determine the relative cost-effectiveness of intensifying LLT for primary prevention based on LDL-C, non-HDL-C, and apoB goals. DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation used a computer simulation model to evaluate the cost-effectiveness of intensifying LLT with high-intensity statins or ezetimibe according to LDL-C, non-HDL-C, or apoB goals. A cohort of 250 000 statin-eligible and atherosclerotic cardiovascular disease-free US adults was constructed from 2005 to 2016 National Health and Nutrition Examination Survey participants (N = 4149). Individuals commenced the simulation after lipid screening and received statin therapy based on 2018 American Heart Association/American College of Cardiology guidelines. Model inputs were derived from national survey data, pooled longitudinal cohort studies, and published literature. Uncertainty was explored with traditional and probabilistic sensitivity analysis. EXPOSURES: Lipid-lowering therapy was intensified if individuals did not achieve treated LDL-C level less than 100 mg/dL, non-HDL-C level less than 118 mg/dL, or apoB level less than 78.7 mg/dL. MAIN OUTCOMES AND MEASURES: Lifetime quality-adjusted life-years (QALYs) and costs (in 2025 US dollars), discounted 3.0% annually. The primary outcome was the incremental cost-effectiveness ratio. Strategies were considered cost-effective if they cost less than $120 000 per QALY gained. RESULTS: Compared with an LDL-C goal, 965 QALYs (95% uncertainty interval [UI], -3551 to 5341 QALYs) would be gained with a non-HDL-C goal, alongside a $2.1 million (95% UI, -$94.2 million to $92.0 million) reduction in costs. Compared with a non-HDL-C goal, 1324 QALYs (95% UI, -2602 to 5669 QALYs) would be gained with an apoB goal, alongside a $40.2 million (95% UI, -$43.6 million to $134 million) increase in costs, yielding an incremental cost-effectiveness ratio of $30 300 per QALY gained. At a willingness-to-pay threshold of $120 000 per QALY gained, an apoB goal was optimal in 65% of probabilistic analyses and a non-HDL-C goal was optimal in 25%. The cost of apoB testing was marginal; higher costs reflected longer life expectancy and prolonged preventive treatment. CONCLUSIONS AND RELEVANCE: The results of this computer simulation study suggest that apoB can be used as a cost-effective marker to guide primary prevention LLT and improve population health.
引用
- Luebbe S, Sniderman AD, Moran AE, et al. Cost-Effectiveness of ApoB, Non-HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy. JAMA. 2026. PMID: 41949879. doi:10.1001/jama.2026.2986
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。